FDA approves first epoetin alfa biosimilar for the treatment of anemia
The U.S. Food and Drug Administration approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney…
Read More...
Read More...